Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Chang, Lei ^a,b,c   Shi, Runlin ^a,b   Yang, Tao ^a,b   Li, Fan ^a,b   Li, Guohao ^c   Guo, Yonglian ^c   Lang, Bin ^d   Yang, Weimin ^a,b   Zhuang, Qianyuan ^a,b   Xu, Hua ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CENTRAL HOSPITAL OF WUHAN   (China)

^d MACAO POLYTECHNIC INSTITUTE   (Macao)

Author keywords

Apoptosis; Bladder cancer; EGFR; Invasion; LRIG1

Indexed keywords

ADENOVIRUS VECTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN 1; MEMBRANE PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; GENETIC THERAPY; HUMANS; MEMBRANE GLYCOPROTEINS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 84889016843     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-101     Document Type: Article

References (30)

1. Cancer statistics, 2008. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. The world health organization/international society of Urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee. Epstein JI, Amin MB, Reuter VR, Mostofi FK, Am J Surg Pathol 1998 22 1435 1448 10.1097/00000478-199812000-00001 9850170 (Pubitemid 28550639)
3. The natural history of bladder cancer. Implications for therapy. Lee R, Droller MJ, Urol Clin North Am 2000 27 1 13 vii 10.1016/S0094-0143(05)70229-9 10696240 (Pubitemid 30085993)
4. Pathways of metastasis suppression in bladder cancer. Said N, Theodorescu D, Cancer Metastasis Rev 2009 28 327 333 10.1007/s10555-009-9197-4 20013033
5. Targeting EGFR in bladder cancer. Villares GJ, Zigler M, Blehm K, Bogdan C, McConkey D, et al. World J Urol 2007 25 573 579 10.1007/s00345-007-0202-7 17690890
6. Epidermal growth factor receptor and bladder cancer: a review. Neal DE, Mellon K, Urol Int 1992 48 365 371 10.1159/000282357 1357809
7. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, et al. J Urol 2008 179 353 358 18006009 (Pubitemid 350216717)
8. Antisense oligonucleotides to the epidermal growth factor receptor. Witters L, Kumar R, Mandal M, Bennett CF, Miraglia L, et al. Breast Cancer Res Treat 1999 53 41 50 10.1023/A:1006127527107 10206071 (Pubitemid 29123618)
9. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Bhuvaneswari R, Gan YY, Soo KC, Olivo M, Mol Cancer 2009 8 94 10.1186/1476-4598-8-94 19878607
10. Cloning, characterization, and expression of human LIG1. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, et al. Biochem Biophys Res Commun 2001 284 1155 1161 10.1006/bbrc.2001.5092 11414704 (Pubitemid 32917959)
11. Characterization and tissue-specific expression of human LRIG2. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, et al. Gene 2004 332 35 43 15145052 (Pubitemid 38624248)
12. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Guo D, Holmlund C, Henriksson R, Hedman H, Genomics 2004 84 157 165 10.1016/j.ygeno.2004.01.013 15203213 (Pubitemid 38760139)
13. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. Gur G, Rubin C, Katz M, Amit I, Citri A, et al. EMBO J 2004 23 3270 3281 10.1038/sj.emboj.7600342 15282549 (Pubitemid 39209151)
14. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, et al. J Biol Chem 2004 279 47050 47056 10.1074/jbc.M409703200 15345710 (Pubitemid 39518360)
15. LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87. Yang WM, Yan ZJ, Ye ZQ, Guo DS, BJU Int 2006 98 898 902 10.1111/j.1464-410X.2006.06405.x 16978290 (Pubitemid 44368046)
16. Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1. Li F, Ye ZQ, Guo DS, Yang WM, Oncol Rep 2011 26 439 446 21567105
17. EGFR inhibitor-mediated apoptosis in solid tumors. Goel S, Hidalgo M, Perez-Soler R, J Exp Ther Oncol 2007 6 305 320 18038764 (Pubitemid 350104820)
18. Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Wang Z, Sengupta R, Banerjee S, Li Y, Zhang Y, et al. Cancer Res 2006 66 7653 7660 10.1158/0008-5472.CAN-06-1019 16885366 (Pubitemid 44289223)
19. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis. Thomasson M, Hedman H, Guo D, Ljungberg B, Henriksson R, Br J Cancer 2003 89 1285 1289 10.1038/sj.bjc.6601208 14520461 (Pubitemid 37363418)
20. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Tanemura A, Nagasawa T, Inui S, Itami S, Dermatol Surg 2005 31 423 430 15871317 (Pubitemid 40489303)
21. LRIG inhibitors of growth factor signalling-double-edged swords in human cancer? Hedman H, Henriksson R, Eur J Cancer 2007 43 676 682 10.1016/j.ejca.2006.10.021 17239582 (Pubitemid 46502902)
22. LRIG1 expression in colorectal cancer. Ljuslinder I, Golovleva I, Palmqvist R, Oberg A, Stenling R, et al. Acta Oncol 2007 46 1118 1122 10.1080/02841860701426823 17851870 (Pubitemid 350058883)
23. LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson JL, et al. Int J Cancer 2011 128 2843 2852 10.1002/ijc.25820 21128282
24. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Yarden Y, Eur J Cancer 2001 37 Suppl 4 3 S8
25. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS, Ann Oncol 2001 12 745 760 10.1023/A:1011177318162 11484948 (Pubitemid 32655082)
26. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR. Wang F, Wang S, Wang Z, Duan J, An T, et al. J Exp Clin Cancer Res 2012 31 65 10.1186/1756-9966-31-65 22901364
27. Epidermal growth factor receptor gene expression and binding capacity in renal cell carcinoma, in relation to tumor stage, grade and DNA ploidy. Ljungberg B, Gafvels M, Damber JE, Urol Res 1994 22 305 308 10.1007/BF00297200 7879316 (Pubitemid 24369386)
28. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. Ye F, Gao Q, Xu T, Zeng L, Ou Y, et al. J Neurooncol 2009 94 183 194 10.1007/s11060-009-9836-1 19300910
29. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, et al. Genes Dev 1998 12 3663 3674 10.1101/gad.12.23.3663 9851973 (Pubitemid 29019647)
30. Signal integration during development: mechanisms of EGFR and Notch pathway function and cross-talk. Doroquez DB, Rebay I, Crit Rev Biochem Mol Biol 2006 41 339 385 10.1080/10409230600914344 17092823 (Pubitemid 44722140)